Computed tomography (CT) imaging has played an instrumental role in assisting clinical diagnosis since its introduction in 1971. CT scanning is a time-efficient, noninvasive procedure that is able to provide the clinician with bone, soft tissue and blood vessel imaging at the same time. This article brings to light new technological advances in CT imaging, with particular focus on spectral detector-based computed tomography (SDCT).
At a continuing medical education webcast hosted by GlaxoSmithKline, Dr Bruce Mungall discussed preventive strategies against invasive meningococcal disease (IMD). Highlights of his presentation are summarized here.
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
At the 42nd Annual Dermatology Conference 2017 held recently in Kuala Lumpur, Professor Michael J. Cork spoke on the interaction between genetic and environmental factors as a primary event in the development of atopic dermatitis (AD) and highlighted the role of topical calcineurin inhibitors (TCIs) in the management of AD.
The addition of an antihypertensive drug from a new class to a patient’s regimen results in huge decreases in systolic blood pressure (SBP) and major cardiovascular (CV) events among those at high risk for CV events but without diabetes, suggests a recent study. Its effects on SBP remain large and similar in magnitude across all levels of baseline drug use and all subgroups of patients.
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Thromboembolism is a major cause of death in patients with cancer, which is why clinicians should check for the symptoms of thromboembolic events right from the initial stages of bevacizumab treatment, suggests a recent study.